SAN DIEGO - September 10, 2012 (Investorideas.com newswire) - Aethlon Medical, Inc. (
OTCBB: AEMD),
disclosed that ThisweekinMedIT.tv (TWIMIT) features an interview with
Chairman and CEO, Jim Joyce regarding the Aethlon ADAPT™ system and
Hemopurifier®. The interview can be accessed on the
company's website.
Aethlon Medical also disclosed that the San Diego Business Journal
(SDBJ) has published an article regarding the company's $6.8 million
contract with the Defense Advanced Research Projects Agency (DARPA) to
develop selective therapeutic filtration technology that would reduce
the incidence of sepsis in wounded warfighters. The
SDBJ article can be accessed on the company's website.
About ThisweekinMedIT.tv
ThisweekinMedIT.tv is a premier medical technology source that
provides the up to date news focusing on the medical and IT industries.
ThisweekinMEDIT.tv (TWIMIT) finds and reports the latest answers to the
healthcare and technology questions, reports on location at the most
talked about events and interviews news breaking medical companies.
Bringing together creditable resources onto one site, TWIMIT works
around the clock "digging deeper" on topics that are important to
healthcare professionals.
About Aethlon Medical
The Aethlon Medical mission is to create innovative medical devices
that address unmet medical needs in cancer, infectious disease, and
other life-threatening conditions. Our Aethlon ADAPT™ System is a
revenue-stage technology platform that provides the basis for a new
class of therapeutics that target the selective removal of disease
enabling particles from the entire circulatory system. The Aethlon
ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address
infectious disease and cancer; HER2osome™ to target HER2+ breast cancer,
and a medical device being developed under a contract with the Defense
Advanced Research Projects Agency (DARPA) that would reduce the
incidence of sepsis in combat-injured soldiers and civilians. For more
information, please visit
www.aethlonmedical.com.
Certain of the statements herein may be forward-looking and involve
risks and uncertainties. Such forward-looking statements involve
assumptions, known and unknown risks, uncertainties and other factors
which may cause the actual results, performance or achievements of
Aethlon Medical, Inc. to be materially different from any future
results, performance, or achievements expressed or implied by the
forward-looking statements. Such potential risks and uncertainties
include, without limitation, the ability for the Company to derive
business partnerships or future revenue streams using the Aethlon ADAPT™
system including the ability to introduce a targeted breast cancer
therapy known as HER2osome™, there is no assurance that FDA will approve
the initiation of the company's clinical programs or provide market
clearance of the company's products, the ability to achieve the goals
set out in the DARPA contract, future human studies of the Aethlon
Hemopurifier® as an adjunct therapy to improve patient responsiveness to
established cancer therapies, the company's ability to raise capital
when needed, the Company's ability to complete the development of its
planned products, the Company's ability to manufacture its products
either internally or through outside companies and provide its services,
the impact of government regulations, patent protection on the
Company's proprietary technology, product liability exposure,
uncertainty of market acceptance, competition, technological change, and
other risk factors. In such instances, actual results could differ
materially as a result of a variety of factors, including the risks
associated with the effect of changing economic conditions and other
risk factors detailed in the Company's Securities and Exchange
Commission filings.
Contacts:
James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
Marc Robins
877.276.2467
mr@aethlonmedical.com
Visit the AETHLON MEDICAL INC (OTC BB: AEMD) showcase profile page on Investorideas.comDisclosure/Disclaimer:
AETHLON MEDICAL INC (OTC BB: AEMD) Investorideas.com is paid by AEMD to
publish news and distribute content through Investordeas.com Newswire
and its syndicated partners and blogs
No comments:
Post a Comment